INF39

製品コードS8559 バッチS855901

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 2 years -80°C liquid
化学式

C12H13ClO2
分子量 224.68 CAS No. 866028-26-4
Solubility (25°C)* 体外  
 
 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

生物活性

製品説明 INF39 is a nontoxic, irreversible NLRP3 inhibitor that counteracts NLRP3 activation through direct irreversible interaction with NLRP3 and partial inhibition of LPS-driven pro-inflammatory gene expression.
in vitro INF39 inhibits NLRP3 ATPase in a concentration-dependent manner and prevents pyroptosis of THP-1 cells. It is able to efficiently inhibit NLRP3-dependent IL-1β release and reduce caspase-1 activation and pyroptosis (measured as extracellular LDH) in macrophages (BMDMs)[1].
in vivo Oral Administration of INF39 reduces systemic and colonic inflammation in rats treated with 2,4-Dinitrobenzenesulfonic acid. Rats treated with INF39 display a significant reduction of macroscopic damage score. Oral administration of INF39 reduces colonic myeloperoxidase, IL-1β, and TNF Levels in DNBS-treated rats. INF39 can exert beneficial effects on colitis, by reducing MPO, IL-1β, and TNF pro inflammatory cytokine levels in colonic tissues from inflamed rats, thus suggesting that the blockade of NLPR3 activation could represent a suitable pharmacological target for the management of intestinal inflammation. INF39, following oral administration, is stable and is absorbed into the intestinal epithelium, where it can act locally and generate the nontoxic metabolites[1].
密度 1.1 g/mL

プロトコル(参考用のみ)

細胞アッセイ 細胞株 THP-1 cells
濃度 0.1−100 μM
反応時間 72 h
実験の流れ

Human THP-1 cells were exposed to increasing concentrations of the synthesized compounds (0.1−100 μM, 72 h), and then cell viability was evaluated by the MTT assay
動物実験 動物モデル Male Sprague−Dawley rats
投薬量 12.5, 25.0, 50.0 mg/kg/day
投与方法 oral administration

カスタマーフィードバック

Data from [Data independently produced by , , Front Pharmacol, 2017, 8:944]

Data from [Data independently produced by , , Biomed Res Int, 2018, doi:10.1155/2018/1294951]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

A new cell death program regulated by toll-like receptor 9 through p38 mitogen-activated protein kinase signaling pathway in a neonatal rat model with sepsis associated encephalopathy [ Chin Med J (Engl), 2022, 135(12):1474-1485] PubMed: 35261352
A Novel Inhibitor INF 39 Promotes Osteogenesis via Blocking the NLRP3/IL-1β Axis [ Biomed Res Int, 2022, 2022:7250578] PubMed: 35872849
NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages [ Int Immunopharmacol, 2021, 92:107358] PubMed: 33508701
TRIM31 inhibits NLRP3 inflammasome and pyroptosis of retinal pigment epithelial cells through ubiquitination of NLRP3 [ Cell Biol Int, 2020, 10.1002/cbin.11429] PubMed: 32716108
Astragaloside IV Suppresses High Glucose-Induced NLRP3 Inflammasome Activation by Inhibiting TLR4/NF-κB and CaSR. [ Mediators Inflamm, 2019, 2019:1082497] PubMed: 30906223
NLRP3 Deficiency Alleviates Severe Acute Pancreatitis and Pancreatitis-Associated Lung Injury in a Mouse Model. [ Biomed Res Int, 2018, 2018:1294951] PubMed: 30622955
NLRP3 Deficiency Alleviates Severe Acute Pancreatitis and Pancreatitis-Associated Lung Injury in a Mouse Model [Qiang Fu, et al. Biomed Res Int, 2018, 10.1155/2018/1294951]
Yupingfeng San Inhibits NLRP3 Inflammasome to Attenuate the Inflammatory Response in Asthma Mice [Liu X, et al. Front Pharmacol, 2017, 8:944] PubMed: 29311942

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。